2564 related articles for article (PubMed ID: 21150868)
21. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
;
MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
23. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
24. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
[TBL] [Abstract][Full Text] [Related]
25. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
Kobayashi M; Pilishvili T; Farrar JL; Leidner AJ; Gierke R; Prasad N; Moro P; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL
MMWR Recomm Rep; 2023 Sep; 72(3):1-39. PubMed ID: 37669242
[No Abstract] [Full Text] [Related]
26. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
27. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
28. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
Paradiso PR
Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
[TBL] [Abstract][Full Text] [Related]
29. Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.
Sucher AJ; Chahine EB; Nelson M; Sucher BJ
Ann Pharmacother; 2011 Dec; 45(12):1516-24. PubMed ID: 22045904
[TBL] [Abstract][Full Text] [Related]
30. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Mokaddas E; Albert MJ
Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
[TBL] [Abstract][Full Text] [Related]
31. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
[TBL] [Abstract][Full Text] [Related]
32. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
33. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
[TBL] [Abstract][Full Text] [Related]
34. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
35. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
Esposito S; Principi N
J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
[TBL] [Abstract][Full Text] [Related]
36. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Kobayashi M; Farrar JL; Gierke R; Leidner AJ; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL; ;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1174-1181. PubMed ID: 36107786
[TBL] [Abstract][Full Text] [Related]
37. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
38. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
39. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
[TBL] [Abstract][Full Text] [Related]
40. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
